Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by amorakon May 11, 2007 12:18pm
386 Views
Post# 12766282

RE: Short position

RE: Short positionI think that more of the folks who took up the January financing shorted just before the stock could become free-trading. Hard to say when or how they'll all cover. We could see more shorting because the participants are under no pressure to convert the debt to stock so time isn't a consideration, just price. They know they can cover easily if they short at current prices. I don't think there will be a short squeeze no matter what happens and I don't think the short position is an indication on the part of the larger market that the RVX share price is expected to drop. For the shorters, they have a guaranteed 30 or 40 percent profit if they short and cover after conversion. If RVX is the big winner we expect then they have their warrants for the home run. So the short position could go up or down but I'm inclined to think down after May 15 because it's rare to have such a high percentage of investors adopting the same strategy. If it goes up then there was a short placed against over 50% of the financing. We'll see, I guess.
Bullboard Posts